SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Gwen Ifill

PatientGwen Ifill
Date of birth1965-09-29
IdentifiersMRN HR-ML032-SYN; SSN (made up) 000-32-5814
Document date2026-06-30
AuthorLorna Achebe-Price, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End of combination treatment: CT result, thyroid tests, and the first maintenance dose. [S]

History of Present Illness

Ms. Ifill returns three weeks after her sixth and last cycle of combination treatment, all given on schedule. The CT a week ago shows no evidence of disease. Over the past month she has felt more tired than after earlier cycles, colder than usual, and a little slowed down, without low mood. The tingling in her toes is unchanged and does not affect walking. She has had no vaginal bleeding, pelvic pain, cough, breathlessness, diarrhea, rash, headache, dizziness or leg swelling. She saw Dr. Delacroix with the CT result and is ready to begin maintenance dostarlimab today. She has had no thoughts of self-harm. [S]

ElementDetail
TreatmentSix cycles of dostarlimab, carboplatin and paclitaxel completed on schedule
ResponseCT: no evidence of disease
New symptomsTiredness and feeling cold for a month
NeuropathyGrade 1, unchanged
TodayFirst maintenance dose of dostarlimab 1000 mg

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired and feels cold; no fever or weight loss
GenitourinaryNegativeNo vaginal bleeding or discharge
GastrointestinalNegativeNo diarrhea, constipation or abdominal pain
RespiratoryNegativeNo cough or breathlessness
NeurologicalPositiveTingling in the toes, unchanged; no headache or dizziness
EndocrinePositiveCold intolerance; no thirst
PsychiatricNegativeMood good; PHQ-9 4; no thoughts of self-harm

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-02-03 to 2026-02-17completedS
Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2026-02-24 to 2026-06-09completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2026-02-24 to 2026-06-30completedS
Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three yearsEvery 6 weeksIntravenous route2026-06-30activeS
Levothyroxine 75 mcg oral tablet, one tablet daily before breakfastOne tablet daily before breakfastOral route2026-06-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-30Body height165cmS
2026-06-30Body weight72.4kgS
2026-06-30Body mass index (BMI) [Ratio]26.6kg/m2S
2026-06-30Systolic blood pressure122mm[Hg]S
2026-06-30Diastolic blood pressure78mm[Hg]S
2026-06-30Heart rate64/minS
2026-06-30Respiratory rate16/minS
2026-06-30Body temperature36.4CelS
2026-06-30Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-30Hemoglobin [Mass/volume] in Blood11.4g/dL12-15.5 g/dLLowS
2026-06-30Leukocytes [#/volume] in Blood by Automated count4.910*3/uL4-11 10*3/uLNormalS
2026-06-30Neutrophils [#/volume] in Blood by Automated count2.810*3/uL1.5-7.7 10*3/uLNormalS
2026-06-30Platelets [#/volume] in Blood by Automated count22810*3/uL150-400 10*3/uLNormalS
2026-06-30Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.59-1.04 mg/dLNormalS
2026-06-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M80mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-30Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
2026-06-30Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-06-30Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L8-35 U/LNormalS
2026-06-30Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-06-30Thyrotropin [Units/volume] in Serum or Plasma11.8m[IU]/L0.4-4.5 mIU/LHighS
2026-06-30Thyroxine (T4) free [Mass/volume] in Serum or Plasma0.7ng/dL0.8-1.8 ng/dLLowS
2026-06-30Cortisol [Mass/volume] in Serum or Plasma13.1ug/dLMorning sample, drawn before 9 a.m.NormalS
2026-06-30Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 2026-06-30; see the Vital Signs section. [S]

SystemFinding
GeneralWell but tired; weight 72.4 kg; blood pressure 122/78, pulse 64, temperature 36.4 °C
NeckThyroid not enlarged or tender
AbdomenSoft, non-tender; no mass
ExtremitiesNo leg swelling; calf circumferences unchanged
NeurologicalPinprick slightly reduced over the toes only; ankle reflexes present with a slow relaxation phase; steady gait
PsychiatricAlert and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review bookedresolvedconfirmed N95.0S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation.
Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial canceractiveconfirmed C54.1S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public.
Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2023 stage IIIC2iiactiveconfirmed C77.8S — Synthetic nodal disease found at surgical staging.
Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities)activeconfirmed G62.0S — Synthetic common effect of paclitaxel.
Immune-related primary hypothyroidism from dostarlimab: TSH 11.8 with a low free T4, tiredness and feeling cold (grade 2)activeconfirmed E03.2S — Synthetic immune-related adverse event, among the most common with PD-1 inhibitors.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingResponse imaging (CT of the chest, abdomen and pelvis)At the end of combination treatmentUp to dateA week ago: no evidence of disease
LaboratoryBlood count with neutrophils and plateletsBefore each cycle; at the end of treatmentCompleted todayHemoglobin 11.4 g/dL, white cells 4.9, neutrophils 2.8, platelets 228; recovered
LaboratoryCreatinine and estimated kidney functionBefore each checkpoint inhibitor doseCompleted todayCreatinine 0.84 mg/dL, eGFR 80
LaboratoryLiver tests (paclitaxel and checkpoint inhibitor)Baseline and before each checkpoint inhibitor doseCompleted todayALT 22, AST 24 U/L, bilirubin 0.5 mg/dL
LaboratoryTSH and free T4 (immune-related thyroid disease)Baseline and before each checkpoint inhibitor doseCompleted todayTSH 11.8 mIU/L and free T4 0.7 ng/dL: immune-related hypothyroidism; levothyroxine started
LaboratoryGlucose (immune-related diabetes)Baseline and before each checkpoint inhibitor doseCompleted today90 mg/dL
LaboratoryMorning cortisol (immune-related adrenal and pituitary disease)Baseline and before each checkpoint inhibitor doseCompleted today13.1 ug/dL, normal; drawn before 9 a.m. under the standing order
LaboratoryCA-125Only if raised at diagnosisNot indicatedNormal at diagnosis (28 U/mL)
ExaminationPeripheral neuropathy: symptoms and examinationAt each visit after taxane treatmentCompleted todayGrade 1, stable
ExaminationLymphedemaEach visit after lymph node surgeryCompleted todayNo swelling
ExaminationImmune-related adverse event symptoms (diarrhea, rash, cough, breathlessness, fatigue, headache)Each visit on a checkpoint inhibitorCompleted todayTiredness and cold intolerance, explained by hypothyroidism; no diarrhea, rash, cough or headache
ExaminationPelvic examinationEvery three months for two yearsDueWith gynecologic oncology in three months
ImagingSurveillance CT of the chest, abdomen and pelvisEvery six months for three years for stage III diseaseDueNext in six months
Medication safetyLevothyroxine: timing and interactionsAt the startCompleted todayTake on an empty stomach before breakfast, four hours apart from calcium or iron
SurveyDistress and depression screen (PHQ-9)At diagnosis, each treatment phase, and when symptoms changeCompleted todayPHQ-9 4
Self-managementSurvivorship care planAt the end of active treatmentCompleted todayWritten plan: visit schedule, symptoms of recurrence to report, lymphedema signs, weight and activity, blood pressure, lipid and glucose care, and screening for other cancers

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023); JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026); Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Preventive visit in six weeks with TSH and free T4, on the day of the second maintenance dose. Gynecologic oncology examination in three months; CT in six months. Call for vaginal bleeding, pelvic pain, cough, diarrhea, rash or breathlessness. Next scheduled visit 2026-08-11: periodic adult preventive visit. [S]